T-Therapeutics appoints Theodora Harold as Chief Executive Officer, reflecting Company’s ambitious growth plans and progression into therapeutic development

Theodora has over 25 years’ experience in the biotech sector, with a proven track record of dynamic leadership.

10 March 2025; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble T cell receptor (TCR) therapeutics targeting cancer and autoimmune indications, announces the appointment of Theodora Harold as its new Chief Executive Officer (CEO). Founder and current CEO of T-Therapeutics Professor Allan Bradley will transition to the role of Chief Scientific Officer.

Theodora has raised significant capital for multiple companies as well as originating and driving numerous, high-profile, business development deals. She brings strong prior experience at the Board level and has held executive leadership positions in development and clinical stage oncology-focused companies, most recently as CEO of Crescendo Biologics. Theodora qualified as a Chartered Accountant with PricewaterhouseCoopers and graduated from the University of Cambridge.

Since its $60 million Series A fundraise at the end of 2023, T-Therapeutics has launched its OpTiMus® platform which is able to address previously intractable TCR targets with fully human, high affinity binders. The OpTiMus platform has now been used to generate a pipeline of first-in-class TCR therapeutics for cancer indications as well as inflammatory disorders. Theodora’s appointment as CEO is designed to support the Company’s transition into the development phase of its highly differentiated assets.

Professor Allan Bradley, Chief Scientific Officer of T-Therapeutics, said: “I am incredibly proud of what our team has already achieved – from developing a best-in-class transgenic mouse platform to securing the support of high-quality investors, and recently demonstrating ground-breaking preclinical activity with our T cell engaging molecules. Now is the right time to hand on the baton and I’m convinced that Theodora’s energetic leadership, capital markets expertise and deep understanding of the T cell landscape will take us further and faster towards our goal of bringing our next-generation TCR medicines to patients. As CSO, I look forward to working closely with her in the months and years ahead.”

Theodora Harold, newly-appointed Chief Executive Officer of T-Therapeutics, said: “I have been very impressed by T-Therapeutics’ world-leading science, the passion of the team and the first-in-class pipeline. The OpTiMus platform is uniquely able to address certain novel TCR targets and thus has the potential to transform the clinical landscape in both cancer and autoimmune diseases. I look forward to working with the Board of Directors, Allan and the whole team as we take the business into the next phase of its development.”

Dr David Hung, Chairman of T-Therapeutics, added:“Theodora’s appointment as our new CEO is a natural next step for T-Therapeutics and I’m delighted we have secured someone of such calibre to the team, who brings a wealth of complementary knowledge and experience. The team will continue to benefit from Allan’s expertise and leadership in his new role as CSO, overseeing the scientific development of our product candidates.”

Contacts

T-Therapeutics
Theodora Harold
info@t-therapeutics.com

ICR Consilium
Amber Fennell, Lucy Featherstone
t-therapeutics@icrhealthcare.com